SCHEMBL2932258

SCHEMBL2932258

COc1cc(Nc2cncc(-c3ccc(O)cc3)n2)c(Cl)cc1C(=O)NCC1CCCO1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.52
ALDH1A1 P00352 8/20 0.48
GAA P10253 4/20 0.48
HPGD P15428 5/20 0.47
TSHR P16473 5/20 0.47
CASP1 P29466 5/20 0.47
CASP7 P55210 5/20 0.47
HSD17B10 Q99714 5/20 0.47
GLA P06280 3/20 0.47
MEN1 O00255 2/20 0.47
MAPT P10636 2/20 0.47
MAPK1 P28482 2/20 0.47
KMT2A Q03164 2/20 0.47
PKM P14618 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HTT P42858 3/20 0.46
POLB P06746 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2933983 0.81 BRAF (0.48) BRAF
SCHEMBL2933848 0.81 HTR4 (0.53) GAASMN1; SMN2BRAF
SCHEMBL4883827 0.80 LMNA (0.51) KDM4EALDH1A1HPGDTSHRHSD17B10
SCHEMBL2933758 0.80 KDR (0.49) ALDH1A1CYP1A2BRAF
SCHEMBL2933849 0.79 BRAF (0.56) BRAF
SCHEMBL2930259 0.79 LMNA (0.54) KDM4EALDH1A1GAAHPGDTSHR
SCHEMBL2933495 0.79 ADRA2A (0.52) ALDH1A1TSHRCYP1A2CYP2C9BRAF
SCHEMBL2930611 0.79 FYN (0.50) MAPTPOLBBRAF
SCHEMBL2934249 0.78 BRAF (0.45) KDM4EBRAF
SCHEMBL2984323 0.78 BRAF (0.45) BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 KDM4E 2380/4885ALDH1A1 3748/4885GAA 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.